Vantage Investment Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

Vantage Investment Advisors’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-200	Closed	-$10K	–	787
2016 Q4	$10K	Hold	200	–	–	﹤0.01%	516
2016 Q3	$7K	Buy	+200	New	+$6.26K	﹤0.01%	563
2015 Q3	–	Sell	-50	Closed	-$3K	–	795
2015 Q2	$3K	Sell	50 -50	-50%	-$3.18K	﹤0.01%	656
2015 Q1	$6K	Buy	+100	New	+$6.79K	﹤0.01%	673
2014 Q3	–	Sell	-1,200	Closed	-$41K	–	749
2014 Q2	$41K	Buy	1,200 +1,150	+2,300%	+$36.2K	0.03%	264
2014 Q1	$2K	Buy	+50	New	+$2.42K	﹤0.01%	604

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Vantage Investment Advisors's IONS Position: Q1 2017 in Review

Vantage Investment Advisors sold out of Ionis Pharmaceuticals (IONS) in Q1 2017, closing a stake of 200 shares — an estimated $10K sold.

Vantage Investment Advisors first reported a position in IONS in Q1 2014 and held it in 6 quarters. The position peaked at $41K in Q2 2014. 270 funds tracked by Wall St. Rank hold IONS as of Q1 2017.

Vantage Investment Advisors reported no remaining Ionis Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Vantage Investment Advisors sold 200 Ionis Pharmaceuticals shares in Q1 2017, an estimated $10K.
Vantage Investment Advisors first reported a position in Ionis Pharmaceuticals in Q1 2014 and held it in 6 quarters.
Vantage Investment Advisors's Ionis Pharmaceuticals position peaked at $41K in Q2 2014.
270 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2017.

Based on Vantage Investment Advisors's 13F filing for Q1 2017, filed 12 May 2017.